NAV

Oxolamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Oxolamine is a medication indicated in the treatment of a cough or upper respiratory tract inflammation.

Generic Name
Oxolamine
DrugBank Accession Number
DB13216
Background

Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant 1. It is listed as a prescription drug in New Zealand legislation 2. Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation 3.

Type
Small Molecule
Groups
Approved
Structure
3D
Similar Structures
Weight
Average: 245.326
Monoisotopic: 245.152812244
Chemical Formula
C14H19N3O
Synonyms
  • Oxolamina
  • Oxolamine
  • Oxolaminum
External IDs
  • 683 M
  • AF 438
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofCoughing••••••••••••
Used in combination for symptomatic treatment ofLaryngitisCombination Product in combination with: Propyphenazone (DB13524)••••••••••••••••••••• ••••••••••••••••
Used in combination for symptomatic treatment ofPharyngitisCombination Product in combination with: Propyphenazone (DB13524)•••••••••••••••••• •••••••••••••••••••
Used in combination for symptomatic treatment ofSinusitisCombination Product in combination with: Propyphenazone (DB13524)••••••••••••••••••••• ••••••••••••••••
Used in combination for symptomatic treatment ofTonsillitisCombination Product in combination with: Propyphenazone (DB13524)••••••••••••••••••••• ••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Oxolamine citrateK5X4XBR6941949-20-8RBZIGQJSMCOHSS-UHFFFAOYSA-N
Oxolamine phosphateDMG78UE3PU131378-45-5PSCWWFOVTFSDGZ-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ASE-COLD 120 mg+50mg+1mg/5 ml PEDİATRİK ŞURUPOxolamine citrate (50 mg/5ml) + Acetaminophen (120 mg/5ml) + Chlorpheniramine maleate (1 mg/5ml)SyrupOralLİLYUM İLAÇ VE KİMYA SAN. TİC. LTD. ŞTİ.2019-05-07Not applicableTurkey flag
FORZA TABLET, 30 ADETOxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine maleate (2 mg) + Phenylephrine hydrochloride (5 mg)TabletOralALİ RAİF İLAÇ SAN. A.Ş.1998-02-17Not applicableTurkey flag
KATARIN 120 MG+50 MG+1 MG/5 ML PEDIATRIK SURUP 100 MLOxolamine citrate (50 mg) + Acetaminophen (120 mg) + Chlorpheniramine maleate (1 mg)SyrupOralBİOFARMA İLAÇ SAN. VE TİC. A.Ş.2003-04-29Not applicableTurkey flag
KATARİN 250 MG/100 MG/2 MG KAPSÜL, 15 ADETOxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine (2 mg)CapsuleOralBİOFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
KATARİN 250 MG/100 MG/2 MG KAPSÜL, 30 ADETOxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine (2 mg)CapsuleOralBİOFARMA İLAÇ SAN. VE TİC. A.Ş.1968-12-09Not applicableTurkey flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PERBRONS 10 MG 120 ML SURUPOxolamine (10 mg)SyrupOralCASEL ECZACI CAHİT SELİMOĞLU İLAÇ SAN. VE TİC. LTD. ŞTİ.2018-12-31Not applicableTurkey flag
PEREBRON 50MG/5 ML 120 ML SURUPOxolamine phosphate (50 mg/5ml)SyrupOralANGELİNİ İLAÇ SAN. VE TİC. A.Ş.2013-01-29Not applicableTurkey flag

Categories

ATC Codes
R05DB07 — Oxolamine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenyloxadiazoles. These are polycyclic aromatic compounds containing a benzene ring linked to a 1,2,4-oxadiazole ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Oxadiazoles
Direct Parent
Phenyloxadiazoles
Alternative Parents
Aralkylamines / Benzene and substituted derivatives / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Amine / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
90BEA145GY
CAS number
959-14-8
InChI Key
IDCHQQSVJAAUQQ-UHFFFAOYSA-N
InChI
InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3
IUPAC Name
diethyl[2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl]amine
SMILES
CCN(CC)CCC1=NC(=NO1)C1=CC=CC=C1

References

General References
  1. NIH - Inxight: Drugs [Link]
  2. New Zealand - Medicines Amendment Regulations 2009 [Link]
  3. Taiwan FDA - News [Link]
  4. TITCK Product Information: Fenko (oxolamine citrate) oral citrate [Link]
ChemSpider
13143
RxNav
32658
ChEBI
94607
ChEMBL
CHEMBL1620875
ZINC
ZINC000000001874
Wikipedia
Oxolamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SyrupOral1200 mg
SyrupOral62.4 mg/5ml
TabletOral
SolutionOral
CapsuleOral
Tablet, coatedOral
SyrupOral50 mg/5ml
Granule, effervescentOral
SyrupOral
SyrupOral10 mg
Pill
Suppository
SyrupOral
Tablet0.2 gr
SyrupOral100 ml
SyrupOral120 ml
SyrupOral1.000 g
Tablet
SuppositoryRectal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.277 mg/mLALOGPS
logP2.7ALOGPS
logP3.14Chemaxon
logS-3ALOGPS
pKa (Strongest Basic)8.96Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area42.16 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity84.15 m3·mol-1Chemaxon
Polarizability28.59 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0kbr-9510000000-ae8477d8fa7555b8a25f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-1090000000-9fe5d65db66ca80d5b64
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-1090000000-89db599e44e327529840
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-1390000000-48ccae45dfc9e4260af6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-1910000000-b5e3bf76e617c52731db
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fb9-9500000000-a39ce233aadb2aadfd24
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fb9-9810000000-c582240cce9652b46c15
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-166.470955
predicted
DarkChem Lite v0.1.0
[M-H]-158.07903
predicted
DeepCCS 1.0 (2019)
[M+H]+166.758455
predicted
DarkChem Lite v0.1.0
[M+H]+160.43703
predicted
DeepCCS 1.0 (2019)
[M+Na]+166.732255
predicted
DarkChem Lite v0.1.0
[M+Na]+166.53017
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:37 / Updated at June 05, 2021 09:13